Free Trial
NYSE:LLY

Eli Lilly and Company Q3 2025 Earnings Report

Eli Lilly and Company logo
$800.07 +0.50 (+0.06%)
As of 09:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company EPS Results

Actual EPS
N/A
Consensus EPS
$6.42
Beat/Miss
N/A
One Year Ago EPS
N/A

Eli Lilly and Company Revenue Results

Actual Revenue
N/A
Expected Revenue
$16.09 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eli Lilly and Company Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, October 29, 2025
Conference Call Time
10:00AM ET

Conference Call Resources

Eli Lilly and Company Earnings Headlines

Never thought I’d see this
Porter Stansberry — founder of one of the world’s largest financial research firms — believes we’re entering a historic economic shift he calls The Final Displacement. Backed by warnings from Nobel Prize winners, this rare event could reshape everything from markets to personal wealth, just as past global displacements toppled empires and created new fortunes. His new investigation reveals why it’s unfolding now, what’s driving it, and how to position yourself on the right side of history.tc pixel
Eli Lilly and Company (LLY): A Bull Case Theory
Eli Lilly and Company (LLY): A Bull Case Theory 
How Eli Lilly became the new king of GLP-1s
See More Eli Lilly and Company Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eli Lilly and Company? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eli Lilly and Company and other key companies, straight to your email.

About Eli Lilly and Company

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical firm headquartered in Indianapolis, Indiana, that discovers, develops, manufactures and markets human pharmaceuticals in a wide range of therapeutic areas. The company’s core focus includes neuroscience, endocrinology, oncology, immunology and cardiovascular disease. Through a vertically integrated research and development model, Eli Lilly advances novel small molecules and biologics from early research through commercialization, serving both adult and pediatric patient populations.

Founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War, the company has grown from a regional drug manufacturer into one of the world’s leading innovators in life sciences. Early achievements included the introduction of insulin for diabetes management in the 1920s and penicillin production during World War II. Over more than a century of operation, Eli Lilly has been credited with pioneering contributions to psychopharmacology, hormone therapies and targeted cancer treatments.

Key marketed products span several disease areas: in diabetes care, it offers rapid- and long-acting insulins as well as injectable GLP-1 receptor agonists; in oncology, its portfolio includes small-molecule kinase inhibitors and immuno-oncology antibodies; and in immunology, the company develops therapies for inflammatory conditions such as rheumatoid arthritis and psoriasis. Complementing these marketed drugs, Lilly maintains an active pipeline with candidates advancing across multiple phases of clinical trials.

Eli Lilly serves patients in more than 120 countries through a combination of direct operations and partnerships. The company emphasizes global manufacturing and supply chain resilience, with major production sites in North America, Europe and Asia. Under the leadership of President and Chief Executive Officer David A. Ricks, Lilly continues to invest heavily in research collaborations, digital health solutions and initiatives to expand access to medicines worldwide.

View Eli Lilly and Company Profile

More Earnings Resources from MarketBeat